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Abstract
Specific general defeat of arteriols, capillaries and veins at a diabet mellitus consists in the bulge of basale membrane of
shallow vessels, laying of glycoproteins in a wall and proliferation of endothelium. A hyperglycaemia results in increasing of
blood plasma, membranes and cages of level of free radicals on a background insufficiency of enzymes of the protective
antioxidant system. Determination of the state insulin tolerance to the people with excessive body weight and obesity, by a
hyperpiesis, problems with the lack of fats, by a gout and other endocrine diseases already on the stage of credible violation
of carbohydrate exchange gives an opportunity in good time to conduct the correction of possible defeats of microvasculature
toxic action of high concentration of glucose.
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A diabetes mellitus DA in the whole world is one of the
most widespread chronic diseases and the global medical
and economic problem of contemporary or present world
[26]. By the considerable increase of morbidity is the last
decades established on a diabetes mellitus in entire countries
and on all continents [11, 20]. This heavy chronic disease,
associated with the increase of risk of development specific
microvascular complicate pathologies of the cardiovascular
system, which brings to early disability and death [1, 6, 13].
A microangiopathy presents by itself specific for a diabete
mellitus general on the level of microvasculature such as
arteriols, tiny veins and capillaries. In the early stage of
illness a diabetic microangiopathy DMA has a characteristic
morphological picture, that consists in the bulge of basale
membrane of shallow vessels, laying of glycoproteins on a
wall, proliferation of endothelium [2, 10].
A general sign of diabetic microangiopathy DMA is the
bulge of basale membrane of capillaries in a skin, muscles,
gastrointestinal tract, nerves, kidneys, fundus of eyes, heart,
placenta, adipose tissue [12, 2]. Diabete mellitus DM and
hyperpiesis HP basic damaging factors result in disfunction
of endothelium, that in turn conduces increasing of enzyme
activity (it converts angiotensin) on the surface of endothelian
cages, hypertension of the tissue renin-angiotensin-aldosteron
system. Activation of enzyme strengthens transformation of
angiotensin-1 in strong vasoconstrictor angiotensin-2, which
has negative influence on utilization of glucose by tissues [6,
17]. An important role is played by the inadequate secretion of
insulin in the damage of endothelial cages, their disfunction.
Thus degree to the hyperglycaemia does not yet cause clinical
symptoms and can exist during the protracted period of time
to the moment of exposure of diabetes mellitus [4, 10]. Ac-
tually, an important role of endothelial disfunction is played
by a hyperglycaemia, surplus of free radicals in circulation
and cellular membranes, lack of fats. Disfunction of endothe-
lium is assisted by the insufficient products of adyponektin,
endogenous antioxidants, fats of high-density. A chronic hy-
perglycaemia causes switching of glucose exchange on the
ways of ”minor” components: sorbite, hecsosamin and finish
products. They activate oxidant reactions, influence on the
synthesis of oxide of nitrogen the cages of endothelium [14,
19].
Vascular pathology of DMA combines with violation of
reologic properties of blood, change properties of blood cages
- thrombocytes, leucocytes and red blood cells. The initial
stages of DM is the violation in a microcirculation compen-
sated by strengthening of capillary blood stream due to cardio-
vascular mechanisms. From data of electronic-microsofic re-
searches the early displays of VIH appeared for 50% patients
with the initial signs of DM. Progress of microangiopathy
results in structural violations of microvasculature and insuffi-
ciency of organs of sight, kidneys, heart, central and peripheral
nervous system, lower limbs. On results positron-emission
of reography the patients of DM of the second type even in
default of atherosclerotic defeats of basic coronal arteries have
decline of coronal reserve on 37% comparatively with such
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for the healthy people of the same age. The size of coronal
reserve mainly depends on the state of arteriols, prearteriols
and capillary degree of vascularization of myocardium [16,
25].
The basic factors of hyperglycaemia in the mechanisms
of development of microangiopathy are:
• Activation of tiop way of exchange of glucose;
• Damages functions of mitochondrium that cause the
blockade of hecsosamin way of metabolism of glucose
and development of basic violation at DM (mitochon-
drian disfunctions);
• increasing of intacellular finish goods of surplus (Ad-
vanced Glycation End-products (AGEs);
• Activation of proteinkinase [6, 13].
A chronic hyperglycaemia is accompanied by increasing gly-
cation of surrounding substrate. Glycated squirrel can accu-
mulate in an endothelium in the basale membrane of shallow
vessels, preventing to the free transport of substrate from
tissues and vice versa.
For DM characteristic combination of insistence is lentin
indicate, decline of oxidization of fats, increase in the cages of
product of lipid exchange of dyacylglycerine. Dyacylglycer-
ine activates proteincinase C, which participates in adjusting
of providing of cages glucose [14, 19].
For patients with clinical displays a change is always
marked as an increase of adgesium of thrombocytes, viscidity
of plasma of blood, decline of deformity of red corpuscles [9,
24].
It is well-proven on this time, that a hyperglycaemia re-
sults in an increase in plasma of blood, membranes and cages
of level of free radicals onabackground insufficiency of en-
zymes of protective antioxidant system- antioxidental stress.
There fore in this difficult multivariable system of violations of
exchange that causes changes in a microvasculature it follows
a starting mechanism to count oxidental stress [8, 18].
Formation of DNA passes for the clinician elusivcly. It
is practically important that the complex rigid control of
glycemia and hypertension definitely reduces the risk of de-
velopment of micro- and macrovascular complications, and
stroke development by 44% [21, 25].
In older people, diabetes is often not diagnosed and re-
mains untreated, and inevitable vascular complications com-
bined with other age-related pathologies significantly impair
the general condition. In 24 cities in the UK, 3642 women
and 3734 men aged 60-79 years were examined. It was found
that 5.7% of men and 5.2% of women were not previously
diagnosed with diabetes (glucose levels 7.0 mmol/l or more,
and 17.3% of British hyperglycemia were onset) [23].
To prevent development of progression of microangiopa-
thy is possible only through full compensation of carbohydrate
metabolism, restoration of physiological sensitivity of tissues
to insulin. A huge clinical study convincingly demonstrated
how much control of glycemia reduces the frequency and
delayed the development of all the complications of diabetes.
Decreasing the level of glycosylated hemoglobin (HbA1c)
by 0.9% (from 7, 9 to 7, 0%) leads to a reduction in overall
mortality by 21%, cardiovascular mortality by 14%, and a
violation of the microcirculation the channel is 37%. When
the HbAlc level decreases by 2%, the mortality risk for pa-
tients with second-degree diabetes is reduced by 42%. Target
indicators of the vaginal exchange that characterize the com-
pensation are close to the physiological. They are in line with
the European guidelines for the second type of diabetes [22].
Glycosylated hemoglobin (HbA1c) <6.5%.
The level of glucose in plasma:
• onset <6.0 mmol/l;
• 2 hours later <7.5 mmol/l.
The blood test for HbA1c has advantages over the blood
sugar analysis that it can be delivered at any time, not neces-
sarily on the nose. It is precise, to hold it faster and easier; to
clearly answer the question: there are people with prediabetes,
diabetes mellitus. The result of the analysis of HbAlc does
not depend on the time, eating, taking medication, exercise,
emotional state of man, colds or other infections. This anal-
ysis describes the state of carbohydrate metabolism over the
past 2-3 months [3, 10].
The result of the analysis on HbA1c allows you to diag-
nose diabetes at an early stage, when the analysis of glycemia
onset still shows that everything in the body is normal. The
main threat of micro- and macrovascular complications in
diabetes of 2-gothipus is considered to be the state of chronic
hyperglycemia. It is known that over 80% of patients with
type 2 diabetes are characterized by excessive massothelium
and obesity.
According to the NHANES (USA) 1999-2000 study, the
prevalence of second-line diabetes in overweight people was
2.9 times higher than that of normal human body mass. With
a body mass index of over 30kg/m2, the risk of developing
type 2 diabetes is 27.6 times higher than with a body mass
index of 22kg/m2 [8].
In 2009-2013, a project to study 20 risk factors in the ur-
ban population of Dnipropetrovsk was implemented. Accord-
ing to this population survey, only 29.9% of the population
had normal body mass, and 70.1% had a totally superfluous
mass and obesity of 1 -3 degrees [17].
The total prevalence of all violations of carbohydrate
metabolism amounted to 77.2% among the urban popula-
tion of Ukraine. Among them, IR was detected in 41.2% of
respondents, glucose intolerance-28%, and the prevalence of
DM 2-nd type was 8% of the total population [17].
With the progression of body weight, the percentage of
detection of IR increased from. 16.8 at normal body weight
to 77.2%, with obesity, the percentage detection of CD - from
3.4 to 16.3, respectively [4].
In many prospective studies, it has been demonstrated that
early carbohydrate disturbances, in particular glucose toler-
ance, are independent of the risk factors for cardiovascular
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disease. The use of antihyperglycemic agents in people with
prediabetes reduces the occurrence of not only type 2 diabetes,
but also the total cardiovascular event.
It is important not to miss the time, to prevent formation
of morphological changes in blood vessels, clinical labora-
tory criteria of diabetes in the implementation of preventive
measures to prevent and treat DMA. The risk of develop-
ment of type 2 diabetes can be reduced (by almost 30%) in
compliance with the regime of non-pharmacological therapy,
lifestyle changes, nutrition, regular physical activity with the
normalization of the mass of visceral adipose tissue [4, 7, 10].
Detection of persons with early violations of carbohydrate
metabolism and preventive interventions is of great medi-
cal and social significance. With the proper organization of
screening in groups of patients with high probability of detect-
ing carbohydrate metabolism disorders, successful primary
prophylaxis of type 2 diabetes at the prediabetes stage can
contribute to a significant decrease in DMA.
The period of determination of the condition of people
with intentional body weight and obesity, hypertension, dipypi-
deemia, gout and other endocrine diseases already at the stage
of pre-diabetes gives the opportunity to timely correct the pos-
sible damage of the microcirculatory channel toxic effects of
high concentrations of glucose and to appoint complex means
of pathogenetic therapy.
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